Human-Centric AI platform for heALth and Life sciencesbroad
HCAI4ALL · Horizon Europe grant · 2023-01-01–2024-12-31
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Abzu ApS – an EU-based deep-tech start-up – is redefining the AI landscape with an explainable, accurate and scalable solution – the QLattice – poised to disrupt the global AI race as the first truly responsible, trustworthy and transparent AI. With EIC support and based on 15+ pharma pilots with second to none explainable and accurate insights, Abzu will develop Reason – a tailor-made platform for pharma readily utilized by non-code savvy R&D scientists. Current black box solutions lack user-friendliness and have failed to restrain steady R&D costs increases in the last 15 years (~€2.5B per drug today). Reason will reverse this trend with added value in key metrics of increased ROI, productivity, and treatment availability. Abzu’s business, technology and the EU’s strategic goals are at a unique crossroads of technological, societal and economic disruption. EIC funds will make Abzu the next EU unicorn and result in the EU disrupting and gaining a foothold in the global AI market.
Beneficiaries (2)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| ABZU APS | DK | coordinator | €2,495,099 | Yes |
| ABZU BARCELONA S.L. | ES | thirdParty | €0 | Yes |
Get the EU Defence Funding Calendar — free
The full calendar of open EU defence and dual-use funding calls, sorted by deadline, updated nightly. Delivered with DFM Analysis, our weekly briefing on who is funding what in European defence.
Or browse all open defence & dual-use calls on the funding calendar →
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; the paid Annual Professional subscription is handled on DFM Analysis.